Small cell lung cancer
Tóm tắt
SCLC is a life-threatening disease, typically caused by cigarette smoking. The incidence has been decreasing during the past decades, probably due to changes in smoking habits. The disease is mostly diagnosed in advanced stage and therefore requires systemic treatment and radiotherapy. Chemotherapy is the most important treatment intervention and a combination of cisplatin + etoposide (EP) represents the standard of care. These tumours are very sensitive to primary treatment with remarkable response rates, although usually of short duration due to resistance. Improvement in outcomes is very hard to obtain in this disease, regardless of treatment intervention – as it has been recognised in the past years. The presentations at this year's ASCO on SCLC underline this dilemma: results of 3 large phase III trials investigating alternative combination chemotherapy regimens with irinotecan, pemetrexed and topotecan failed to improve outcome when compared to standard treatment with EP. A further report of a phase III trial underlined the current standard of 25 Gy PCI dose in LD-SCLC complete responders with no additional benefit of a higher PCI dose. Progress in the treatment of SCLC – if any – remains to be slow in the light of the presented results.
Tài liệu tham khảo
Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines, 2nd edn. Chest, 132(3 suppl): 324S–339S, 2007
Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med, 346(2): 85–91, 2002
Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol, 24(13): 2038–2043, 2006
Natale R, Lara P, Chansky K, et al. S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). J Clin Oncol, 26(May 20 suppl): abstr 7512, 2008
Socinski MA, Weissman C, Hart LL, et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol, 24(30): 4840–4847, 2006
Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol, 14(8): 2345–2352, 1996
Quoix E, Breton JL, Gervais R, et al. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Lung Cancer, 49(2): 253–261, 2005
Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst, 87(3): 183–190, 1995
Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med, 357(7): 664–672, 2007
Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med, 341(7): 476–484, 1999
Le Pechoux C, Hatton M, Kobierska A, et al. Randomized trial of standard dose to a higher dose prophylactic cranial irradiation (PCI) in limited-stage small cell cancer (SCLC) complete responders (CR): Primary endpoint analysis (PCI99-01, IFCT 99-01, EORTC 22003-08004, RTOG 0212). J Clin Oncol, 26(May 20 suppl): abstr LBA7514, 2008